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Syngeneic cellsA major obstacle to obtaining relevant results in cancer vaccination has been the lack of identification of
immunogenic antigens. Dendritic cell (DC)-based cancer vaccines used preventively may afford protec-
tion against tumor inoculation, but the effect of antigen choice on anti-tumor protection is not clear.
When using irradiated syngeneic tumor cells to load DCs, tumor self-antigens are provided, including
tumor-associated antigens (TAAs) and neoantigens generated by tumor mutations. On the other hand,
allogeneic tumor cells could only supply shared TAAs. To assess the advantages of each source in protec-
tive vaccination, we analyzed in C57BL/6 mice the effect of loading DCs with irradiated syngeneic B16-F1
or allogeneic Cloudman melanoma cells; both cell lines were characterized by whole exome sequencing
and RNAseq. Tumor cell components from the two irradiated cell lines were efficiently internalized by
DCs, and transported to MHC-class II positive tubulovesicular compartments (MIICs). DCs loaded with
allogeneic irradiated Cloudman cells (DC-ApoNecALLO) induced a partially effective anti-melanoma pro-
tection, although Cloudman and B16-F1 cells share the expression of melanocyte differentiation antigens
(MDAs), cancer-testis antigens (CTAs) and other TAAs. DCs loaded with syngeneic B16-F1 cells (DC-
ApoNecSYN) established a more potent and long-lasting protection and induced a humoral anti-B16F1
response, thus suggesting that neoepitopes are needed for inducing long-lasting protection.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction In melanoma, immunogenic TAAs have been described,For the past decades, clinical trials on cancer vaccines have
given modest results (reviewed in [1]). One of the major obstacles
has been the inability to clearly identify relevant immunogenic
antigens.including melanocyte differentiation antigens (MDAs) such as
Melan-A, Pmel/gp100 and Tyr [2–4], and Cancer-Testis-Antigens
(CTAs) [5–7]. On the other hand, human melanoma is the
cancer with the highest somatic mutation prevalence [8].
Non-synonymous mutations in the coding regions of the genome
can give rise to neoepitopes, given that mutated proteins are
expressed and their peptides presented by the patient’s MHC-I
and MHC-II molecules to specific CD8+ and CD4+ T lymphocytes
[9]. In the context of cancer immunotherapy, neoepitope-specific
T lymphocytes have not been clonally deleted and should be able
to mount an effective immune response [9,10]. Neoantigen reac-
tive T cells have been identified in several cancers, including mel-
anoma [11,12] and personalized cancer vaccines targeting
neoantigens are already being tested in clinical trials [13]. DCs play
Table 1







4948 S. Mac Keon et al. / Vaccine 37 (2019) 4947–4955a key role in vaccination, as they are capable of capturing, process-
ing and presenting antigens to naïve T cells. When allogeneic
tumor cells are used as source of antigen in DC-based vaccination,
MDAs like Pmel and Melan-A are efficiently cross-presented to
specific CD8 T cells [14] and measurable immune responses against
such MDAs were observed in patients [15].
We have previously developed an experimental preventive
anti-melanoma vaccine consisting of DCs loaded with syngeneic
irradiated murine melanoma cells (DC-ApoNec vaccine), which
provides long-term anti-B16-F1 melanoma protection [16,17].
Using this system, we have now analyzed in C57BL/6 mice the
effect of a syngeneic (H-2b haplotype) versus an allogeneic (H-2d
haplotype) melanoma antigen source in DC-based preventive vac-
cination. DCs were loaded with irradiated syngeneic B16-F1 cells
(DC-ApoNec SYN) or allogeneic Cloudman melanoma cells (DC-
ApoNec ALLO). If neoepitopes were the only antigens to trigger
immune protection, then only DC-ApoNec SYN would be a success-
ful vaccine. If, on the contrary, TAAs shared by allogeneic tumors
are also useful antigens, vaccination with DC-ApoNec ALLO would
have some efficacy. We performed high throughput exome and
RNA sequencing to establish the antigenic repertoire of both cell
lines. We demonstrate that while vaccination with DC-ApoNec ALLO
induces partially effective protection, DC-ApoNec SYN establishes a
more potent and long-lasting protection.2. Material and methods
2.1. Mice and tumor cell lines
Eight-12-week-old male mice maintained in pathogen-free con-
ditions were used. C57BL/6J mice were purchased from the Fun-
dación Instituto Leloir (Buenos Aires, Argentina) and MHC-II-GFP
mice were kindly provided by the Hidde Ploegh Laborator [18].
Studies were performed in accordance to protocols approved by
the Animal Care and Use Committee of the Fundación Instituto
Leloir and of the University of Pennsylvania and CHOP.
B16-F1 cell line was purchased from the ATCC and cultured in
DMEM (Sigma) 4,5 g/l glucose containing 10% FBS (Natocor, Argen-
tina). Cloudman S91 cell line was purchased from the ATCC and
cultured in DMEM 4,5 g/l glucose containing 15% FBS. H5V cell line
(Istituto di Ricerche Farmacologiche Mario Negri, Milan) was cul-
tured in DMEM 1 g/l glucose containing 10% FBS. 4T1 cell line
was generously provided by Dr. Osvaldo Podhajcer (Fundación
Instituto Leloir) and cultured in RPMI (Sigma) containing 10%
FBS. Cells were maintained in culture for no >10 passages in
100 U/ml penicillin and 100 mg/ml streptomycin (Rochet) supple-
mented media and were periodically tested negative for
mycoplasma.
2.2. Quantitative real-time PCR
mRNA levels were quantified as previously described [19].
Briefly, PCR runs were carried out using SYBR Universal Master
Mix (Applied Biosystems, Carlsbad, CA, USA), and relative expres-
sion levels were determined by the DDCt method [20] using actb
gene expression to normalize all samples (Ct: Threshold Cycle).
The primers used are listed in Table 1.
2.3. Induction of apoptosis and necrosis
B16-F1 and Cloudman cells were c-irradiated (70 Gy, Siemens
lineal accelerator, Instituto Alexander Fleming, Buenos Aires) and
stored in liquid nitrogen. Cells were thawed and cultured using
the corresponding culture media for each cell line. Non-adherent
and adherent cells were collected. Apoptosis and necrosis weredetermined with FITC-Annexin V (AnV) – propidium iodide (PI)
Apoptosis Detection Kit I (BD Biosciences) following the manufac-
turer’s recommendations, measured by flow cytometry (FACSCal-
ibur Flow Cytometer, Becton Dickinson) and analyzed using
FlowJo 7.6 software.
2.4. Isolation and culture of bone marrow-derived DCs
Bone marrow DC progenitors were obtained from the femurs
and tibias of 8–12-week-old C57BL/6 mice and differentiated to
DCs in RPMI containing 0.02 mg/ml recombinant murine GM-CSF
(Peprotech, Mexico), as previously described [17].
2.5. Incorporation of ApoNec cells by DCs and immunofluorescence
analysis of maturation markers
ApoNec cells were stained with PKH26 (Sigma) following the
manufacturer’s recommendations and cultured with DCs for 24 h
at 37 C followed by 1 h at 4 C incubation with anti-CD11c-PE-
cy7 antibody (Ab) (Clone HL3, BD biosciences). Immunofluores-
cence was assessed by flow cytometry and analyzed using FlowJo
7.6 software.
Non-stained ApoNec cells were cultured with DCs for 24 h at
37 C, incubated for 15 min at 4 C with mouse Fc-block, and incu-
bated for another 45 min at 4 C with PE-anti-mouse CD11c (Clo-
neHL3), FITC-anti-mouse I-Ab (Clone AF6-120.1) or FITC-anti-
mouse CD86 (Clone GL.1) (all Abs from BD Biosciences). Cells were
then washed with PBS and fixed with 2% PFA. Immunofluorescence
was quantified by flow cytometry and data analyzed using FlowJo
7.6 software.
2.6. Live cell imaging
MHC-II –GFP DCs were adhered ON to poly-L-lysine–coated
glass-bottom 35-mm culture dishes (MatTek, Ashland, MA), co-
cultured for 3 or 7 h on a 1:1 ratio with PKH26 pre-stained ApoNec
cells (Sigma) and visualized as described in [21].
2.7. Transmission electron microscopy
DCs were co-cultured with ApoNec cells in a 1:1 ratio for 24 h at
37 C, detached with DMEM, washed with 0.1 M pH 7.4 phosphate
buffer, fixed for 4 h at 4 C in 2.5% glutaraldehyde, washed again,
and post-fixed first in osmium tetroxide and then in uranyl acetate
prior to dehydration. Cells were visualized using a Zeiss EM 10C
transmission electron microscope (LANAIS, Buenos Aires,
Argentina).
2.8. Confocal microscopy
DCs were adhered ON to glass-bottomed plates, and co-cultured
for 6 h with Celltrace violet-stained ApoNec cells on a 1:1 ratio,
fixed with 2% PFA and permeabilized with Permwash (BD
biosciences) and sequentially stained with rat-anti-Lamp1 Ab
(clone 1D4B) and anti-rat-Alexa488 Ab in 0.1% saponin in PBS for
1 h. Stained cells were visualized using a BioVision spinning disk
S. Mac Keon et al. / Vaccine 37 (2019) 4947–4955 4949system on a Leica DMI8 microscope, and images were captured on
a Hamamatsu Orca Flash 4.0 V2 CMOS camera and Visiview soft-
ware (Dept. of Pathology & Laboratory Medicine, Children’s Hospi-
tal of Philadelphia). ImageJ (National Institutes of Health) was used
for the posterior analysis of the images.2.9. DC-ApoNec preventive vaccination
DC-ApoNec vaccine was prepared and administered as
described in [17]. Briefly, DCs and ApoNec cells were co-cultured
in a 1:1 ratio for 24 h and resuspended in PBS. Four doses of
2  105 DC-ApoNec were administrated s.c. every 14 days in the
inguinal region of the same flank. Two weeks after, 1.5  104 viable
B16-F1 cells were administered s.c. on the contralateral flank to the
vaccination site. Mice were monitored every two days for tumor
growth by palpation, and tumor size was measured with a Vernier
caliper. Animals were euthanized when tumors displayed ulcera-
tion or a size 500 mm3.2.10. Humoral response
At days 28-34th after tumor challenge, blood samples were
obtained by sub-mandibular bleeding and serum stored at
80 C until used.
To determine the presence of serum Abs by FACS, 2  105 B16-
F1 cells were incubated with 10% normal goat serum, centrifuged
5 min at 300 g at 4 C, incubated for 60 min at 4 C with serum
dilutions, washed with PBS, incubated 30 min with a 1/100 dilu-
tion of RPE-goat anti-mouse Immunoglobulins (R0480, Dako),
washed with PBS and fixed with 2% PFA. Mean Fluorescence Inten-
sities (MFI) were analyzed in a FACScalibur cytometer.
For ELISA, B16-F1 cells and C57Bl/6 splenocyte monolayers on
96-well cell culture plates were fixed with 4% PFA for 15 min at
room temperature, blocked with 100 ml 1% BSA in PBS for 1 h, incu-
bated overnight at 4 C with 75 ml of 1/200 serum dilutions in 0.1%
BSA in PBS, washed 3 times with 150 ml 0.1% BSA in PBS, incubated
with 100 ml 1/10000 dilution in 0.1% BSA in PBS of HRP-AffiniPure F
(ab0)2 Fragment Goat Anti-Mouse IgG (H + L) (Jackson ImmunoRe-
search) and washed 3 times with 150 ml 0.1% BSA in PBS. TMB
(Sigma) was used to detect HRP activity, and the reaction was
stopped with 2 M H2SO4. Absorbance at 450 nm was assessed.Fig. 1. MDA expression and apoptosis induction after c-irradiation. (A) mRNA levels for
were calculated using B16-F1 and Cloudman Cts compared to H5V endothelial cells Cts.
shown. (Student́s t test, p > 0.05). (B) B16-F1 and Cloudman cells were c-irradiated (70 G
percentages of apoptotic/necrotic cells were assessed by flow cytometry.2.11. Western blot analysis
50 mg protein of B16-F1 or skeletal muscle lysates (used as con-
trol, data not shown) were run on 8% SDS–PAGE gels, transferred to
nitrocellulose membranes, blocked for 1 h at room temperature,
incubated overnight at 4 C with a 1/100 serum dilution from pro-
tected mice (4 mice pooled per group), washed, and stained with
peroxidase-conjugated rabbit anti mouse IgG + A + M specific sec-
ondary antibody (Zymed) for 1 h at room temperature. The bound
antibody was detected using SuperSignalTM West Pico PLUS Chemi-
luminescent Substrate (Thermo Scientific) according to the manu-
facturer’s protocol. Imaging was performed on an LAS 500 scanner
(GE).
2.12. IFN-c enzyme-linked immunospot assay (ELISPOT)
Splenocytes were seeded (1  106) in 24-well plates in 1 ml of
complete medium consisting of RPMI containing 10% FBS, 2 mM
glutamine, 100 U/mL penicillin, 100 mg/ml streptomycin, 10 mM
HEPES, 50 mM 2-mercaptoethanol and 100 U/mL of human IL-2
(Laboratorio Pablo Cassará SRL, Argentina). B16-F1 lysate was
added (lysate from 70,000 B16-F1 cells/1  106 splenocytes) and
they were cultured at 37 C for 12 days. Every 3 days, fresh com-
plete medium with IL-2 was added. Murine IFN-c Elispot Set (BD
Biosciences) was used and manufacturer’s instructions were fol-
lowed. Harvested splenocytes from 12-day culture were added to
the IFN-c-coated plates (2  105 cells/well) and cultured with
complete medium with B16-F1 lysate for 18 h at 37 C. As positive
control 20 ng/ml PMA + 1 mg/ml Ionomycin was used (data not
shown). Spots were visualized by adding 50 ll/well of AEC Sub-
strate (BD Biosciences) for 2 min. Substrate reaction was stopped
by washing the plate with deionized water. Plates were scanned
using an AID iSPOT ELR088IFL analyzer.
2.13. High throughput sequencing
Snap-frozen pellets were prepared from C57Bl/6 splenocytes,
B16-F1, Cloudman and 4T1 cells. DNA and RNA extraction,
sequencing and standard bioinformatic analysis were all per-
formed by BGI Tech Solutions (Hong Kong). Whole exome sequenc-
ing: Agilent SureSelect Mouse Exon (50 Mb), 50 coverage, and
then sequencing (PE150). RNAseq: Illumina HiSeq400 100PEMDAs were assessed by qRT-PCR in B16-F1 and Cloudman cells. The 2-DDCt values
Actb was used as reference gene. Mean ± SD from two independent experiments is
y) and cultured for 0, 24 or 48 h. They were then stained with AnV-FITC and IP, and
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mation was graphed using Plotly. The MHC-I binding predictions
were made using the IEDB analysis resource Consensus tool [22]
which combines predictions from ANN aka NetMHC (4.0) [23–
25], SMM [26] and Comblib [27]. The predicted output is given in
units of IC50 nM. FPKM values of the analyzed genes are included
on Supplementary Table II. The raw data is available at the Geo
Database online repository, series record GSE109268 provides
access to the data.2.14. Statistical methods
GraphPad Prism version 5.00 Software (San Diego, USA) and
Infostat version 2016 (Córdoba, Argentina) were used to graph data
and perform statistical analysis.Fig. 2. Internalization of ApoNec cells by DCs. (A) ApoNec SYN or ApoNec ALLO cells we
binding). DCs were stained with anti-CD11c Ab, and PKH26 incorporation in CD11c+ cell
dotplots from a representative experiment are shown. The percentage of incorporation of
cells. Mean ± SD from three independent experiments is shown. (Student́s t test, a = 0.05
with anti-CD11c Ab and either anti-I-Ab or anti-CD86 antibody and analyzed by flow cyto
t test was used to compare DC-ApoNec SYN and DC-ApoNec ALLO (a = 0.05, n = 3, *p < 0.05)
showing membrane ruffles and multiple endocytic/phagocytic compartments, some lo
pigment granules (white arrows) shown at higher magnification (50,000). (iii) DC sh
Macropinosomes (black arrows) shown at higher magnification (50,000). (D) DCs were c
lysosomes in DCs were stained using anti-Lamp-1 Ab (green) and visualized using confoca
reader is referred to the web version of this article.)3. Results
3.1. B16-F1 and Cloudman melanoma cells are efficient sources of
MDAs.
We investigated the expression of MDAs by the syngeneic B16-
F1 (H-2b haplotype) and the allogeneic Cloudman (H-2d haplotype)
melanoma cell lines. Messenger RNA levels were quantified by
qRT-PCR (Fig. 1A). Both melanoma cell lines expressed Tyr, Dct
(Trp-2), Mlana (Melan-A) and Pmel, and no significant differences
in expression were observed between the two cell lines. Further-
more, both underwent apoptosis after 70 Gy irradiation, with
>50% of irradiated cells staining positive for Annexin V after 48 h
of culture (Fig. 1B) and displaying lack of proliferative capacity col-
ony forming assay in soft agar (data not shown). Thus, 48-hour
post-irradiation cells (ApoNec) were later used to load DCs.re stained with PKH26 and cultured with DCs for 24 h at 37 C or 4 C (unspecific
s was assessed by flow cytometry. Three independent experiments were performed,
ApoNec cells by DCs was assessed as the percentage of CD11c+ PKH26+ cells/CD11c+
, n = 3, p > 0.05). (B) MHC-II and CD86 MFI on DC-ApoNec was assessed by staining
metry. Lipopolysaccharide (LPS)-treated DCs were used as positive control. Student’s
. (C) Transmission electron microscopy of DC-ApoNec SYN and DC-ApoNec ALLO (i) DC
aded with pigment (7000). (ii) Endocytic/phagocytic compartments containing
owing membrane ruffles and endocytic/phagocytic compartments (12,000). (iv)
ultured for 6 hs with Celltrace violet-stained ApoNec SYN or ApoNec ALLO (red). Then,
l microscopy. (For interpretation of the references to colour in this figure legend, the
S. Mac Keon et al. / Vaccine 37 (2019) 4947–4955 49513.2. B16-F1 and Cloudman irradiated cells are incorporated by CD11c+
cells and are transported within MIIC
B16-F1 and Cloudman ApoNec cells were labelled with PKH26
and co-cultured in vitro with immature DCs at 37 C or 4 C
(unspecific binding). After 24 h, 60.3 ± 21.1% and 71.0 ± 19.4% of
CD11c+ cells internalized cell components from B16-F1 ApoNec
or Cloudman ApoNec cells respectively (Fig. 2A). Cloudman Apo-
Nec loaded DCs (DC-ApoNec ALLO) significantly upregulated surface
MHC-II compared to B16-F1 ApoNec loaded DCs (DC-ApoNec SYN),
while surface CD86 expression was not affected (Fig. 2B).
We also analyzed by electron microscopy morphologic features
of DC-ApoNec SYN and DC-ApoNecALLO (Fig. 2C). In DC-ApoNecSYN
and DC-ApoNec ALLO we observed numerous endocytic/phagocytic
compartments, some containing melanin (Fig. 2C). ApoNec cell-
derived material was also probably incorporated by macropinocy-
tosis, as membrane ruffling could be observed in DCs and
flocculent material could be observed in intracellular compart-
ments (Fig. 2C iv). After 6 h of co-culture, ApoNec material
localized to vesicles that were labeled for lysosomal associated
membrane protein 1 (LAMP1) vesicles in DCs (Fig. 2D), suggesting
that the majority of ApoNec-containing endosomes/phagosomes
had matured and fused with lysosomes.
Peptide loading on MHC-II molecules occurs within MHC-II-
containing compartments (MIIC) [28]. MHC-II GFP-expressing
DCs were used to identify MIIC and their interaction with incorpo-
rated ApoNec material (Fig. 3). We observed ApoNec materialFig. 3. MIIC in DC-ApoNec cells. ApoNec SYN or ApoNec ALLO were stained with PKH26
visualized by spinning-disk confocal microscopy.within MIIC at 3 and 7 h of co-culture, and are also present within
extensive dynamic tubules that emerged from these compartments
(Movies S1–S4); such tubules have been shown to facilitate either
cell surface expression of peptide-MHC-II complexes from
endolysosomes [29,30] or mixing of phagosome contents for
enhanced MHC class II presentation from phagosomes [31].3.3. Partially effective melanoma protection is induced by vaccination
with DCs loaded with Cloudman ApoNec cells
It has been previously demonstrated that vaccination with
DC-ApoNec SYN is effective and long-lasting [16]. To test whether
DC-ApoNec ALLO could also elicit effective long-lasting melanoma
protection, four s.c. doses of 2  105 DC-ApoNec ALLO or
DC-ApoNec SYN were administered to C57Bl/6 mice, one every
14 days. Unloaded DCs were administered as control of unspecific
immune activation, and PBS (vehicle) was administered as nega-
tive control. Fourteen days after completion of the vaccination
scheme, 1.5  104 viable B16-F1 cells were s.c. injected, and the
animals were monitored for tumor growth.
DC-ApoNecSYN vaccination induced complete protection, with
100% of vaccinated animals remaining tumor-free 10 weeks after
tumor challenge (Fig. 4A). By comparison, DC-ApoNec ALLO vaccina-
tion induced partially effective anti-melanoma protection, as 60%
of the animals remained tumor-free, with a significant difference
in protection between DC-ApoNec SYN and DC-ApoNec ALLO vaccina-
tions (p < 0.05). Tumor-free animals were rechallenged twoand cultured with MHC-II GFP-expressing DCs. At 3 or 7 h of co-culture DCs were
Fig. 4. Tumor protection elicited by DC-ApoNec SYN and DC-ApoNec ALLO vaccination. (A) Kaplan Meier analysis showing the percentage of tumor-free animals following
tumor challenge: four s.c. doses of DC-ApoNec SYN or DC-ApoNec ALLO vaccines were administered (one dose every 14 days). Fourteen days after completion of the vaccination
scheme, 1.5  104 viable B16-F1 cells were administered s.c., and the animals were monitored for tumor growth for the following 60 days. One representative experiment of
two independent experiments is shown. Statistical analysis: Logrank Test was performed for each group against the control group (PBS) (n = 10, a = 0.05, *p < 0.05,
***p < 0.001). (B) Kaplan Meier analysis showing the percentage of tumor-free animals following tumor rechallenge: 2 months after B16-F1 administration, tumor-free
animals were rechallenged with another s.c. injection of 1.5  104 viable B16-F1 cells and the animals were monitored for tumor growth for the following 10 weeks.
Statistical analysis: Logrank Test (6  n  9, a = 0.05, p < 0.05) (C) Anti-B16-F1 Abs induced by vaccination. B16-F1 viable cells were incubated with sera obtained one month
after tumor challenge (1:200, 1:400, 1:800, 1:1600 and 1:3200 dilutions) and then incubated with RPE-anti-mouse immunoglobulins Ab. Geo Mean RPE-Fluorescence
Intensities were assessed by flow cytometry. Mice protected by DC-ApoNecALLO vaccination (P) or non-protected (NP) were analyzed as separate groups. Sera obtained from
unvaccinated/unchallenged mice were used as control. Mean ± SD is shown (3  n  5, a = 0.05). Geo mean values between treatments (1:200 serum dilution) were
compared using the nonparametric Kruskal Wallis Test, and as Post-Test, Dunn’s Multiple Comparison Test was performed to compare each treatment against control sera.
(D) Serum anti-B16-F1 IgG induced by vaccination by ELISA. B16-F1 cells were plated on 96-well cell culture plates, fixed with 4% PFA and incubated with 1/200 serum
dilutions obtained from vaccinated and protected animals. HRP-AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch) 1/10,000 dilution was
used as secondary Ab. Absorbance at 450 nm was assessed. Statistical analysis was performed using Kruskal Wallis non-parametric test and Dunńs Multiple Comparison Test
was used to compare each treatment against PBS (a = 0.05, n = 4) (E) Western blot analysis of B16F1 cell lysate with serum from PBS-treated mice, DC-ApoNecSYN or DC-
ApoNecALLO vaccinated and protected mice, with detection using HRP- rabbit anti mouse IgG + A + M specific secondary antibody. Shown is one representative of two
independent experiments. (F) IFN-y ELISPOT. Splenocytes (Sp) were obtained from vaccinated animals 10 weeks following tumor challenge, or at the time of sacrifice in the
non-protected animals, pooled (n = 4), and cultured for 12 days with medium containing B16-F1 lysate. ELISPOT was performed by incubating the Sp with B16-F1 lysate for
24 hs. As positive control we incubated the Sp with 20 ng/ml PMA + 1 mg/ml Ionomycin (not shown). Three independent experiments were performed. Elispot plates and
counts (in white) shown correspond to a representative experiment.
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1.5  104 viable B16-F1 cells and observed for an additional
60 days. DC-ApoNec SYN vaccinated mice remained tumor-free,
while there was a significant decrease in protection in mice vacci-
nated with DC-ApoNec ALLO (Fig. 4B).
3.4. Humoral and cellular response to B16-F1 cells is induced by DC-
ApoNec SYN vaccination
In order to analyze if an anti-B16-F1 humoral response target-
ing surface antigens was induced by DC-ApoNec vaccination, sera
were obtained one month after tumor challenge to assess anti-
B16-F1 Abs. For this, viable B16-F1 cells were incubated with
increasing serum dilutions, followed by incubation with a PE-
conjugated Ab specific for mouse immunoglobulins. Immunofluo-
rescence was analyzed by flow cytometry (Fig. 4C). Compared to
control sera from PBS and DCs-treated mice, DC-ApoNec SYN
induced a significant anti-B16-F1 humoral response (p < 0.05). Incontrast, there was no significant humoral anti-B16-F1 response
with DC-ApoNec ALLO vaccination (p > 0.05). Additionally, we ana-
lyzed by ELISA the induction of anti-B16-F1 IgG antibodies and
observed again that only DC-ApoNec SYN induced a significant
response (p < 0.01) (Fig. 4D). We did not observe serum reactivity
from vaccinated mice towards normal C57Bl/6 cells (data not
shown). We performed Western blots to analyze the pattern of
anti-B16-F1 antigens recognized by sera from protected mice,
and observed that the majority of the proteins recognized were
not shared between DC-ApoNec SYN and DC-ApoNec ALLO sera
(Fig. 4E). There were two bands of approximately 150 kDa detected
by both DC-ApoNec SYN and DC-ApoNec ALLO sera.
Additionally, we isolated splenocytes from vaccinated animals
10 weeks following tumor challenge or at the time of sacrifice in
the non-protected animals, cultured them for 12 days with med-
ium containing B16-F1 lysate, and then performed an IFN-y ELI-
SPOT assay adding B16-F1 lysate for 18 h. We observed higher
IFN-y production by splenocytes from animals vaccinated with
Fig. 5. Antigenic profile of the cell lines as determined by RNAseq. Relative mRNA expression (log10 (FPKM + 1)) by B16-F1 and Cloudman melanoma cells. As non-
melanocytic allogeneic cell line mammary carcinoma 4T1 cells were used. MDAs (dark grey), CTAs (medium grey) and other TAAs (light grey).
S. Mac Keon et al. / Vaccine 37 (2019) 4947–4955 4953DC-ApoNec SYN than from those vaccinated with DC-ApoNec ALLO
or controls (Fig. 4F).
3.5. High throughput genomic and transcriptomic analysis of B16-F1
and Cloudman cell lines
To determine the antigenic repertoire of B16-F1 and Cloudman
cells, and of 4T1 cells as a non-melanocytic control, we analyzed
their exome sequence and their transcriptome. To identify
tumor-specific mutations B16-F1 cells were compared to normal
C57Bl/6 splenocytes. 1041 new nonsynonymous somatic point
mutations were identified, with 291 of them in expressed genes.
Of such mutated proteins, only 5 were shared by B16-F1 and
Cloudman cells (Supplementary Figure 1 and Supplementary
Table I) and have poor predicted H-2 binding affinities, so they
have a low probability to be efficiently presented to CD8 T cells
in C57Bl/6 mice. Thus, it is unlikely that anti-melanoma protection
provided by DC-ApoNec ALLO was due to such shared mutated pro-
teins. The rest of the 286 mutated B16-F1 proteins could provide
neoepitope candidates not shared by Cloudman cells. We have also
detected 12 frameshift variant insertions and deletions in B16-F1
expressed genes that could provide neoepitope candidates, and
are not shared by Cloudman cells.
We investigated by RNAseq analysis if there were other TAAs
being expressed by B16-F1 and Cloudman cells that could beinvolved in anti-melanoma protection (Fig. 5). As expected, B16-
F1 and Cloudman shared very high expression of MDAs. Interest-
ingly, they both shared the expression of other TAAs as Spag9
and Maged2 and several CTAs, such as Odf2, Kif2c, Ddx20 and Lrwd1
(Supplementary Table II).4. Discussion and conclusions
Preventive vaccination with DC-ApoNec SYN has proven to
induce a significantly higher long-term protection than vaccination
with DC-ApoNecALLO. We determined by transcriptome analysis
that Cloudman cells are a good source of melanoma TAAs, includ-
ing CTAs and high levels of MDAs. On the contrary, they do not
share B16-F1 neoepitopes for MHC class I presentation, as the
few identified shared mutations do not have strong predicted
MHC-I binding affinities. We therefore conclude that shared MDAs,
CTAs or other TAAs, are only capable of eliciting partial anti-
melanoma protection. If we consider that with DC-ApoNec ALLO
vaccination 60% of the animals remain tumor-free after the first
tumor challenge, and of these 56% remain tumor-free after the sec-
ond challenge, only 34% overall protection is achieved compared to
100% protection induced by DC-ApoNecSYN. These data would sup-
port the conclusion that shared TAAs are not capable of inducing
long-term protection and that self-antigens/neoepitopes present
4954 S. Mac Keon et al. / Vaccine 37 (2019) 4947–4955in syngeneic cells are necessary to induce a potent long-lasting
anti-melanoma protection.
B16-F1 and Cloudman melanoma cell lines undergo apoptosis
after 70 Gy irradiation and are efficiently internalized by bone-
marrow derived DCs. ApoNec material localizes to mature endoly-
somes, phagosomes and derived tubules that also harbor MHC-II
molecules in DCs, suggesting that ApoNec-derived material can
be efficiently processed for T-cell presentation. The only difference
observed was a significant upregulation of surface MHC-II in DCs
loaded with allogeneic cells, but this was not accompanied by
upregulation of other costimulatory molecules as CD86, and ulti-
mately did not induce a potent anti-tumoral protection.
It is noteworthy that DC-ApoNec SYN vaccination induces a very
high level of anti-B16-F1 IgG Abs. Although vaccination in cancer
aims to generate a long-lasting response dependent on antigen-
specific CD8 T cells that generate cytotoxic T lymphocytes capable
of killing tumor cells [32], it has also become evident from studies
with anti-TAA monclonal Abs that these collaborate with T cells to
amplify anti-tumor responses. Ab effector-mediated tumor cell
killing potentially leading to antigen spreading and an inflamma-
tory reprogramming of the tumor microenvironment have been
described [33]. We observe that vaccination with DC-ApoNec SYN
significantly induces IgG Abs directed towards B16-F1 proteins.
Nonetheless, by Western blot we also detected some reactivity of
DC-ApoNec ALLO sera towards B16-F1 antigens, and most of the
bands recognized are not shared between DC-ApoNec SYN and
DC-ApoNec ALLO vaccinated mice. It would be important to deter-
mine the lytic effect of these Abs against B16-F1 tumor cells, which
could be particularly interesting when targeting cell-surface
antigens.
RNAseq analysis was performed to determine the antigenic
repertoire shared between B16-F1 and Cloudman melanoma cells
lines. Apart from MDAs, we searched for other TAAs that could
explain the partial protection induced by DC-ApoNec ALLO vaccina-
tion. The expression of Cancer-testis antigens (CTAs) are restricted
in healthy adults to male germ cells and placenta, but are ectopi-
cally expressed in many human tumors [34]. Thus, CTAs could be
considered tumor-specific antigens capable of inducing cancer-
restricted immune responses [35], and could be more immuno-
genic than MDAs, which are constitutively present in melanocytes.
In support of this notion, B16-F1 and Cloudman cells share the
expression of testis-restricted CTAs like Odf2, Kif2c, Ddx20, Lrwd1,
Boris, Acrbp and Tsga10, which provide epitopes with strong pre-
dicted binding affinities. Most of these CTAs have cytoplasmic or
nuclear expression, so they could be only involved in CD8 T cell
responses. Many known human CTAs have not been analyzed in
this work as testis-restricted CTAs differ between humans and
mice, as shown when analyzing RNA profiling data sets generated
by the mouse ENCODE project.
This work suggests that TAAs and CTAs shared by B16-F1 and
Cloudman tumor cells constitute partially effective target antigens
for DC-based anti-melanoma preventive vaccination. The higher
level of protection achieved by loading DCs with B16-F1 melanoma
cells suggests that neoepitopes are needed for inducing long-
lasting protection. It has recently become clear that mutated
neoantigens are an important target of antitumor T cell responses,
but unfortunately not all tumors have a high/relevant number of
mutations, and they are typically patient-specific. Thus, further
study of shared tumor antigens needs to be developed as an alter-
native immunotherapeutic approach.Funding
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